亚宝药业：亚宝投资所持有的公司股份累计质押股份数为3860万股

Group 1 - The core point of the article is that Yabao Pharmaceutical has significant shareholding and pledge details from its controlling shareholder, along with its revenue composition for the upcoming year [1] Group 2 - As of the announcement date, Yabao Pharmaceutical's controlling shareholder, Shanxi Yabao Investment Group, holds 94.3 million shares, accounting for 13.47% of the total share capital [1] - The total number of pledged shares by Yabao Investment is 38.6 million, which represents 40.93% of its holdings and 5.51% of the company's total share capital [1] - For the year 2024, Yabao Pharmaceutical's revenue composition is projected to be 75.46% from pharmaceutical manufacturing, 21.37% from pharmaceutical wholesale, 1.88% from other trading, and 1.29% from other businesses [1] - The current market capitalization of Yabao Pharmaceutical is 4.6 billion yuan [1]